Practice Points

Pharmacological therapy of female urinary incontinence

Diaa E. E. Rizk

Department of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, United Arab Emirates University, Al-Ain, United Arab Emirates.

Abstract

Background: Although not a life threatening condition, UI is a common problem in women that produces embarrassing and debilitating symptoms, severely affects the quality of life and represents a significant public health problem. The bladder and urethra in women constitute a functional unit that is controlled by a complex interplay between the central and peripheral cholinergic and noradrenergic nervous systems and local regulatory factors. A substantial part of urethral tone in women is also mediated through the effect of estrogen on urethral mucosal function. Theoretically, detrusor instability can be improved by agents that decrease detrusor contractility and genuine stress incontinence by agents that increase outlet resistance.

Objective: To review the use of various drugs in treatment of female urinary incontinence [UI] and present the current evidence-based recommendations.

Methods: Systematic review of literature

Results: The strength of evidence for the use of such agents, however, varies from data obtained from pharmacological and physiological experiments to those derived from clinical studies. Hence, the use of some of the currently prescribed drugs for treatment of female UI is founded more on tradition than on evidence based on results from controlled clinical trials. There is also an urgent medical need for a new smooth muscle agent for treating UI in women because current drug therapy of UI is either inadequate or ineffective. Therefore, further clinical experience with drugs that selectively modulate the electrophysiological properties and the intracellular pathways of the smooth muscles of the lower urinary tract in women as therapeutic agents for UI is awaited with interest.

Key words: Drugs, pharmacology, urinary incontinence, women.

Introduction

Urinary incontinence [UI] is a common distressing and disabling condition causing significant physical and psychological morbidity in women of all ages. Female UI can result from a number of factors such as weakness of the urethral sphincter mechanism (genuine stress incontinence- GSI), diminished bladder capacity or compliance, inadequate bladder sensation and neurological dysfunction (detrusor instability- DI) and genito-urinary fistulas.

The bladder and urethra in women constitute a functional unit that is controlled by a complex interplay between the central and peripheral nervous systems and local regulatory factors. The detrusor muscle is diffusely and richly supplied with cholinergic nerve fibers from S2-S4. Muscarinic receptors are located predominantly in the body of the bladder. Acetylcholine acts on these receptors to cause a contractile response. Parasympathetic efferents to the bladder also innervate the urethral smooth muscle and cholinergic stimulation produces contraction. The functional significance of this response in women is however unknown. Several subpopulations of muscarinic receptors have been identified (M1-M5) all with a wide distribution in the body. The M3 receptor is thought to mediate bladder contraction.

The presence of noradrenergic terminals in the human bladder from T10-L2 is controversial. In several mammalian species, a receptor sites producing contraction in response to noradrenaline binding have been shown to predominate in the bladder base whilst b receptors (primarily b2 receptors) producing relaxation, are predominant in the vault. The female urethral smooth muscle contains minimal a adrenergic receptors, primarily a2, which elicit a contractile response when stimulated. A substantial part of urethral tone in women is also mediated through the effect of estrogen on urethral mucosal function.

Principles of pharmacological therapy

Theoretically, DI can be improved by agents that decrease detrusor contractility and GSI by agents that increase outlet resistance. The strength of evidence for the use of such agents, however, varies from data obtained from pharmacological and physiological experiments to those derived from clinical studies (Tables 1,2).
Table 1. Drug therapy recommendations for detrusor instability (drugs that decrease uncontrolled detrusor contractions).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage range</th>
<th>Side Effects</th>
<th>Comments</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1- Propanthelene bromide</td>
<td>15-30 mg up to q.i.d. if needed</td>
<td>Anticholinergic effects such as dry mouth, constipation, blurred vision</td>
<td>Contraindicated in narrow-angle glaucoma</td>
<td>A</td>
</tr>
<tr>
<td>2- Trospium chloride</td>
<td>20 mg b.d.</td>
<td>”</td>
<td>”</td>
<td>B</td>
</tr>
<tr>
<td>3- Tolterodine tartate</td>
<td>1-2 mg b.d.</td>
<td>Anticholinergic effects but less dry mouth</td>
<td>”</td>
<td>A</td>
</tr>
<tr>
<td>4- Oxybutynin chloride</td>
<td>2.5-5mg up to t.d.s as needed</td>
<td>Anticholinergic effects</td>
<td>”</td>
<td>A</td>
</tr>
<tr>
<td>5- Imipramine</td>
<td>25 mg nocte up to t.d.s if needed</td>
<td>Postural hypotension, hepatotoxic, abdominal pain, Anticholinergic effects</td>
<td>Contraindicated with mono-ama oxidase inhibitors</td>
<td>B</td>
</tr>
<tr>
<td>6- Flavoxate</td>
<td>100-200 mg nocte up to q.i.d. if needed</td>
<td>Anticholinergic effects</td>
<td>Contraindicated in narrow-angle glaucoma</td>
<td>C</td>
</tr>
</tbody>
</table>

A= Evidence from at least one randomised controlled clinical trial.
B= Evidence from at least one controlled clinical studies but not randomised trials.
C= Evidence from expert committee reports and/or clinical experiences of respected authorities without directly applicable clinical studies.

Table 2. Drug therapy recommendations for genuine stress incontinence (drugs that increase bladder outlet resistance).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Dosage range</th>
<th>Side Effects</th>
<th>Comments</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1- Phenylpropanol-amine</td>
<td>75 mg b.d.</td>
<td>Hypertension, insomnia, tremors, palpitations</td>
<td>Contraindicated with mono-ama oxidase inhibitors and in patients with hypertension and narrow-angle glaucoma</td>
<td>B</td>
</tr>
<tr>
<td>2- Pseudo-ephedrine</td>
<td>25-50 mg up to q.i.d. if needed</td>
<td>”</td>
<td>”</td>
<td>B</td>
</tr>
<tr>
<td>3- Estrogen</td>
<td>0.625 mg o.d. or topical cream 1gm 1-2 times/week</td>
<td>Estrogen side effects</td>
<td>Add progesterone in patients who have a uterus and are taking estrogen orally</td>
<td>C</td>
</tr>
<tr>
<td>4- Imipramine</td>
<td>25 mg nocte up to t.d.s if needed</td>
<td>Postural hypotension, hepatotoxic, abdominal pain,</td>
<td>Contraindicated with mono-ama oxidase inhibitors</td>
<td>C</td>
</tr>
</tbody>
</table>

A= Evidence from at least one randomised controlled clinical trial.
B= Evidence from at least one controlled clinical studies but not randomised trials.
C= Evidence from expert committee reports and/or clinical experiences of respected authorities without directly applicable clinical studies.
I- Agents that decrease bladder contractility (Table 1)

1- Antimuscarinic (Anticholinergic) drugs
Muscarinic receptors mediate not only normal bladder contraction but also the principal contractions of the unstable bladder. Antimuscarinic agents are currently the most widely used treatment for DI but they lack selectivity for the bladder and effects on other organ systems may result in anticholinergic side effects that limit their usefulness.

Propantheline bromide is a quaternary ammonium compound with a documented effect on detrusor hyperactivity in most clinical studies and may in individually titrated doses be clinically useful. However, in a recent randomized, double-blind, multicentre trial, there was no differences between the efficacy of propantheline and placebo for the treatment of DI.

Trospium chloride is another quaternary ammonium compound with antimuscarinic actions, but also with effects on ganglia. Several open studies have indicated that the drug may be useful in the treatment of DI with fewer side effects compared to other antimuscarinic agents. Trospium chloride has also a documented effect on detrusor hyperactivity in in-vitro studies.

Tolterodine tartate is a new potent and competitive antagonist at muscarinic receptors, intended for the treatment of DI. The drug has no selectivity for muscarinic receptor subtypes, but still shows some selectivity for the bladder over the salivary glands in animal models and possibly in man. Several randomized, double-blind, placebo-controlled studies on patients with DI have documented significant reduction in symptoms and the drug was also well tolerated with long-lasting effects on the bladder.

2- Drugs with ‘mixed’ actions
Some drugs have a pronounced antimuscarinic effect and an often poorly defined “direct” action on bladder muscle that may involve blockade of voltage-operated calcium channels. Among the drugs with mixed actions was terodiline, which was withdrawn from the market because it was suspected to cause polymorphic ventricular tachycardia.

Oxybutynin chloride has several pharmacological effects, some of which seem difficult to relate to its effectiveness in the treatment of DI. It has both an antimuscarinic and a direct muscle-relaxant effect, and local anaesthetic actions. Oxybutynin has a high affinity for muscarinic receptors in human bladder tissue and effectively blocks carbachol-induced contractions. Several studies, both open and controlled, have shown that oxybutynin is effective in controlling DI. The therapeutic effect of oxybutynin is however associated with a high incidence of side effects (up to 80% with oral administration). These are typical antimuscarinic and are often dose-limiting. Therefore, forms of oxybutynin other than the conventional 5mg tablet have been introduced; rectal and intravesical administration and a controlled-release preparation, administered once daily, were reported to have fewer adverse effects. Oxybutynin thus has a well-documented efficacy in the treatment of DI and is currently, despite its adverse effect profile, the drug of first choice and the gold standard for treatment of this disorder.

Antidepressants have been found to have beneficial effects in patients with DI. However, imipramine is the only drug that has been widely used clinically to treat this disorder. Imipramine has complex pharmacological effects, including marked systemic anticholinergic actions and blockade of the re-uptake of serotonin but its mode of action in DI has not been established. Several investigators have shown that the drug can be effective in the treatment of bladder hyperactivity although it is well established that therapeutic doses may cause serious toxic effects on the cardiovascular system.

Flavoxate has mixed actions but the main mechanism by which this drug exerts an effect on smooth muscle has not been established. The drug has moderate calcium antagonistic activity, can inhibit phosphodiesterase and has local anaesthetic properties and a mild anticholinergic effect. The clinical effects of flavoxate in DI have been studied in both open and controlled investigations, but with varying rates of success. In general, few side effects have been reported during treatment with flavoxate but its efficacy, compared with other therapeutic alternatives, is not well documented.

b Adrenoceptor agonists have a pronounced inhibitory effect on isolated human bladder and the administration of such drugs can increase bladder capacity in man. Favourable effects on bladder hyperactivity were reported in open studies with selective b2 adrenoceptor agonists such as terbutaline. However, other investigators have not been able to show this effect. Moreover, b adrenoceptor-mediated responses of the human bladder has recently been shown to be mediated by a β3 adrenoceptor but whether stimulation of this receptor will be an effective way of treating the unstable bladder has yet to be shown in controlled clinical trials.
II- Agents that increase urethral outlet resistance (Table 2)

\(\alpha\) Adrenoceptor agonists: Several drugs with agonistic effects on \(\alpha\) adrenoceptors have been tried as a treatment of GSI but ephedrine and norephedrine (phenylpropanolamine) seem to be the most widely used drugs and have both been reported to be effective\(^{10,11}\). Both drugs directly stimulate \(\alpha\) and \(\beta\) adrenoceptors and can also release noradrenaline from adrenergic nerve terminals. These drugs however lack selectivity for urethral \(\alpha_2\) adrenoceptors and may increase blood pressure. Attempts have thus been made to develop agonists with selectivity for the human urethra, but presently, no such drug is available.

\(\textbf{Estrogen:}\) The role of estrogen in the treatment of GSI has been controversial, even though there are several reported studies\(^{18}\). Some have given promising results but this may be because they were observational, not randomized, blinded or controlled. The situation is further complicated because several different types of estrogen have been used with varying doses, routes of administration and duration of treatment. A recent meta-analysis, however found that estrogen therapy alone was not an effective treatment for this condition but may have a role when combined with other therapies such as \(\alpha\) adrenoceptor agonists\(^{18}\).

\(\textbf{Imipramine:}\) Imipramine inhibits the re-uptake of noradrenaline in adrenergic nerve endings and this can be expected to enhance the contractile effects of noradrenaline on urethral smooth muscle\(^{11}\). However, no controlled clinical trials on the effects of imipramine in GSI are available\(^{15}\).

### Table 3. New pharmacological modalities for treatment of female urinary incontinence.

<table>
<thead>
<tr>
<th>Drug</th>
<th>Pharmacological principle of action</th>
<th>Potential use</th>
<th>Evidence</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Potassium channel openers</td>
<td>Decrease purinergic detrusor contractions</td>
<td>Detrusor instability</td>
<td>B</td>
</tr>
<tr>
<td>2. Calcium antagonists</td>
<td>Decrease influx of extracellular calcium</td>
<td>&quot;</td>
<td>B</td>
</tr>
<tr>
<td>3. Propiverine</td>
<td>Mixed anti-cholinergic and calcium antagonist effects</td>
<td>&quot;</td>
<td>B</td>
</tr>
<tr>
<td>4. Darifenacin and Vamicamide antagonists</td>
<td>Selective M3 receptor antagonist effects</td>
<td>&quot;</td>
<td>B</td>
</tr>
<tr>
<td>5. Intravesical capsaicin and resiniferatoxin</td>
<td>Desensitize C-fibre sensory afferents of the urinary bladder</td>
<td>&quot;</td>
<td>B</td>
</tr>
<tr>
<td>6. Selective phosphodiesterase inhibitors (vinpocetine)</td>
<td>Inhibit actin/myosin phosphorylation</td>
<td>&quot;</td>
<td>D</td>
</tr>
<tr>
<td>7. Duloxetine</td>
<td>Inhibits catecholamine re-uptake in the striated urethral sphincter</td>
<td>Genuine stress incontinence</td>
<td>B</td>
</tr>
<tr>
<td>8. Intravesical prostaglandins contractions</td>
<td>Decrease unstable detrusor</td>
<td>Detrusor instability</td>
<td>C</td>
</tr>
</tbody>
</table>

B= Evidence from at least one controlled clinical studies but not randomised trials.
C= Evidence from expert committee reports and/or clinical experiences of respected authorities without directly applicable clinical studies.
D= Evidence from pharmacological studies or physiological experiments.
**New pharmacological modalities for treatment of female UI (Table 3).**

**Potassium channel openers**

In many animal models and the isolated human bladder, anticholinergic drugs only partially antagonize the cholinergic contractile response. The most widely accepted explanation is that a major portion of neurotransmission involved in bladder contraction is non-adrenergic, non-cholinergic. A purinergic system releasing adenosine 5'-triphosphate [ATP] that acts on a subtype of purinoceptors called P2x or the ATP-sensitive potassium channel seems to be the most likely mechanism. Potassium channel openers are a newly developed group of smooth muscle relaxants that decrease membrane excitability by acting on these channels in the cell membrane to increase potassium efflux resulting in membrane hyperpolarization and reduction of opening probability of ion channels involved in depolarization. The best known and most clinically tested members of the group are pinacidil and cromakalim. Several experimental and clinical studies have shown that both drugs reduce bladder contractions induced by electrical stimulation, carbachol and detrusor hyperactivity which may be useful in the treatment of DI as a supplement or alternative to anticholinergic drugs.

**Calcium antagonists**: The activation of detrusor muscle, both through muscarinic receptor and non-adrenergic, non-cholinergic pathways seems to require the influx of extracellular calcium ions through calcium channels as well as via mobilization of intracellular calcium. The former pathway can be blocked by calcium antagonists and theoretically this would be an attractive way of inhibiting detrusor hyperactivity. However, there have been few clinical trials of the effects of these drugs on DI. Oral nifedipine or intravesical verapamil were not found to be effective in most studies but the latter produced objective improvement in urodynamic variables. Calcium antagonists may also enhance the effects of antimuscarinic agents in DI.

**Propiverine**: Propiverine is a new drug that has combined anticholinergic and calcium antagonistic actions and has been shown to have beneficial effects on detrusor hyperactivity in several investigations. Controlled clinical trials have also confirmed the efficacy of propiverine in patients with DI and suggested that the drug may have equal efficacy with and fewer side effects than oxybutynin.

**Duloxetine**: Duloxetine is a combined noradrenaline and serotonin re-uptake inhibitor that has been shown, in animal experiments, to increase the neural activity to the external urethral sphincter. In clinical studies, the drug was effective in treatment of GSI in women and well tolerated with few side effects. Further recent evidence for the safety and efficacy of duloxetine has accumulated from a number of multicentre placebo-controlled trials.

**Intravesical prostaglandins**: The human bladder mucosa has the ability to synthesize eicosanoids and these agents can be liberated from bladder muscle and mucosa in response to different types of trauma. It is still unclear whether prostaglandins contribute to the pathogenesis of unstable bladder, anticholinergic drugs only partially antagonize the cholinergic contractile response. The most widely accepted explanation is that a major portion of neurotransmission involved in bladder contraction is non-adrenergic, non-cholinergic. A purinergic system releasing adenosine 5'-triphosphate [ATP] that acts on a subtype of purinoceptors called P2x or the ATP-sensitive potassium channel seems to be the most likely mechanism. Potassium channel openers are a newly developed group of smooth muscle relaxants that decrease membrane excitability by acting on these channels in the cell membrane to increase potassium efflux resulting in membrane hyperpolarization and reduction of opening probability of ion channels involved in depolarization. The best known and most clinically tested members of the group are pinacidil and cromakalim. Several experimental and clinical studies have shown that both drugs reduce bladder contractions induced by electrical stimulation, carbachol and detrusor hyperactivity which may be useful in the treatment of DI as a supplement or alternative to anticholinergic drugs.

**Calcium antagonists**: The activation of detrusor muscle, both through muscarinic receptor and non-adrenergic, non-cholinergic pathways seems to require the influx of extracellular calcium ions through calcium channels as well as via mobilization of intracellular calcium. The former pathway can be blocked by calcium antagonists and theoretically this would be an attractive way of inhibiting detrusor hyperactivity. However, there have been few clinical trials of the effects of these drugs on DI. Oral nifedipine or intravesical verapamil were not found to be effective in most studies but the latter produced objective improvement in urodynamic variables. Calcium antagonists may also enhance the effects of antimuscarinic agents in DI.

**Propiverine**: Propiverine is a new drug that has combined anticholinergic and calcium antagonistic actions and has been shown to have beneficial effects on detrusor hyperactivity in several investigations. Controlled clinical trials have also confirmed the efficacy of propiverine in patients with DI and suggested that the drug may have equal efficacy with and fewer side effects than oxybutynin.

**Duloxetine**: Duloxetine is a combined noradrenaline and serotonin re-uptake inhibitor that has been shown, in animal experiments, to increase the neural activity to the external urethral sphincter. In clinical studies, the drug was effective in treatment of GSI in women and well tolerated with few side effects. Further recent evidence for the safety and efficacy of duloxetine has accumulated from a number of multicentre placebo-controlled trials.

**Intravesical prostaglandins**: The human bladder mucosa has the ability to synthesize eicosanoids and these agents can be liberated from bladder muscle and mucosa in response to different types of trauma. It is still unclear whether prostaglandins contribute to the pathogenesis of unstable bladder, anticholinergic drugs only partially antagonize the cholinergic contractile response. The most widely accepted explanation is that a major portion of neurotransmission involved in bladder contraction is non-adrenergic, non-cholinergic. A purinergic system releasing adenosine 5'-triphosphate [ATP] that acts on a subtype of purinoceptors called P2x or the ATP-sensitive potassium channel seems to be the most likely mechanism. Potassium channel openers are a newly developed group of smooth muscle relaxants that decrease membrane excitability by acting on these channels in the cell membrane to increase potassium efflux resulting in membrane hyperpolarization and reduction of opening probability of ion channels involved in depolarization. The best known and most clinically tested members of the group are pinacidil and cromakalim. Several experimental and clinical studies have shown that both drugs reduce bladder contractions induced by electrical stimulation, carbachol and detrusor hyperactivity which may be useful in the treatment of DI as a supplement or alternative to anticholinergic drugs.

**Calcium antagonists**: The activation of detrusor muscle, both through muscarinic receptor and non-adrenergic, non-cholinergic pathways seems to require the influx of extracellular calcium ions through calcium channels as well as via mobilization of intracellular calcium. The former pathway can be blocked by calcium antagonists and theoretically this would be an attractive way of inhibiting detrusor hyperactivity. However, there have been few clinical trials of the effects of these drugs on DI. Oral nifedipine or intravesical verapamil were not found to be effective in most studies but the latter produced objective improvement in urodynamic variables. Calcium antagonists may also enhance the effects of antimuscarinic agents in DI.

**Propiverine**: Propiverine is a new drug that has combined anticholinergic and calcium antagonistic actions and has been shown to have beneficial effects on detrusor hyperactivity in several investigations. Controlled clinical trials have also confirmed the efficacy of propiverine in patients with DI and suggested that the drug may have equal efficacy with and fewer side effects than oxybutynin.

**Duloxetine**: Duloxetine is a combined noradrenaline and serotonin re-uptake inhibitor that has been shown, in animal experiments, to increase the neural activity to the external urethral sphincter. In clinical studies, the drug was effective in treatment of GSI in women and well tolerated with few side effects. Further recent evidence for the safety and efficacy of duloxetine has accumulated from a number of multicentre placebo-controlled trials.

**Intravesical prostaglandins**: The human bladder mucosa has the ability to synthesize eicosanoids and these agents can be liberated from bladder muscle and mucosa in response to different types of trauma. It is still unclear whether prostaglandins contribute to the pathogenesis of unstable bladder, anticholinergic drugs only partially antagonize the cholinergic contractile response. The most widely accepted explanation is that a major portion of neurotransmission involved in bladder contraction is non-adrenergic, non-cholinergic. A purinergic system releasing adenosine 5'-triphosphate [ATP] that acts on a subtype of purinoceptors called P2x or the ATP-sensitive potassium channel seems to be the most likely mechanism. Potassium channel openers are a newly developed group of smooth muscle relaxants that decrease membrane excitability by acting on these channels in the cell membrane to increase potassium efflux resulting in membrane hyperpolarization and reduction of opening probability of ion channels involved in depolarization. The best known and most clinically tested members of the group are pinacidil and cromakalim. Several experimental and clinical studies have shown that both drugs reduce bladder contractions induced by electrical stimulation, carbachol and detrusor hyperactivity which may be useful in the treatment of DI as a supplement or alternative to anticholinergic drugs.

**Calcium antagonists**: The activation of detrusor muscle, both through muscarinic receptor and non-adrenergic, non-cholinergic pathways seems to require the influx of extracellular calcium ions through calcium channels as well as via mobilization of intracellular calcium. The former pathway can be blocked by calcium antagonists and theoretically this would be an attractive way of inhibiting detrusor hyperactivity. However, there have been few clinical trials of the effects of these drugs on DI. Oral nifedipine or intravesical verapamil were not found to be effective in most studies but the latter produced objective improvement in urodynamic variables. Calcium antagonists may also enhance the effects of antimuscarinic agents in DI.

**Propiverine**: Propiverine is a new drug that has combined anticholinergic and calcium antagonistic actions and has been shown to have beneficial effects on detrusor hyperactivity in several investigations. Controlled clinical trials have also confirmed the efficacy of propiverine in patients with DI and suggested that the drug may have equal efficacy with and fewer side effects than oxybutynin.

**Duloxetine**: Duloxetine is a combined noradrenaline and serotonin re-uptake inhibitor that has been shown, in animal experiments, to increase the neural activity to the external urethral sphincter. In clinical studies, the drug was effective in treatment of GSI in women and well tolerated with few side effects. Further recent evidence for the safety and efficacy of duloxetine has accumulated from a number of multicentre placebo-controlled trials.

**Intravesical prostaglandins**: The human bladder mucosa has the ability to synthesize eicosanoids and these agents can be liberated from bladder muscle and mucosa in response to different types of trauma. It is still unclear whether prostaglandins contribute to the pathogenesis of unstable bladder, anticholinergic drugs only partially antagonize the cholinergic contractile response. The most widely accepted explanation is that a major portion of neurotransmission involved in bladder contraction is non-adrenergic, non-cholinergic. A purinergic system releasing adenosine 5'-triphosphate [ATP] that acts on a subtype of purinoceptors called P2x or the ATP-sensitive potassium channel seems to be the most likely mechanism. Potassium channel openers are a newly developed group of smooth muscle relaxants that decrease membrane excitability by acting on these channels in the cell membrane to increase potassium efflux resulting in membrane hyperpolarization and reduction of opening probability of ion channels involved in depolarization. The best known and most clinically tested members of the group are pinacidil and cromakalim. Several experimental and clinical studies have shown that both drugs reduce bladder contractions induced by electrical stimulation, carbachol and detrusor hyperactivity which may be useful in the treatment of DI as a supplement or alternative to anticholinergic drugs.

**Calcium antagonists**: The activation of detrusor muscle, both through muscarinic receptor and non-adrenergic, non-cholinergic pathways seems to require the influx of extracellular calcium ions through calcium channels as well as via mobilization of intracellular calcium. The former pathway can be blocked by calcium antagonists and theoretically this would be an attractive way of inhibiting detrusor hyperactivity. However, there have been few clinical trials of the effects of these drugs on DI. Oral nifedipine or intravesical verapamil were not found to be effective in most studies but the latter produced objective improvement in urodynamic variables. Calcium antagonists may also enhance the effects of antimuscarinic agents in DI.

**Propiverine**: Propiverine is a new drug that has combined anticholinergic and calcium antagonistic actions and has been shown to have beneficial effects on detrusor hyperactivity in several investigations. Controlled clinical trials have also confirmed the efficacy of propiverine in patients with DI and suggested that the drug may have equal efficacy with and fewer side effects than oxybutynin.
detrusor contractions but these substances may sensitize the sensory afferent nerves of the bladder increasing the afferent input produced by a given degree of bladder filling and triggering involuntary bladder contractions. Treatment of DI with intravesical prostaglandins or with prostaglandin synthesis inhibitors could be expected to be effective if this is an important mechanism. However, clinical evidence for this is still lacking.

CONCLUSION
Although not a life threatening condition, UI is a common problem in women that produces embarrassing and debilitating symptoms, severely affects the quality of life and represents a significant public health problem. The use of some of the currently prescribed drugs for treatment of female UI is, however, founded more on tradition than on evidence based on results from controlled clinical trials. According to current recommendations (Tables 1, 2), anticholinergic agents particularly oxybutynin chloride or tolterodine tartate is usually considered the drugs of first choice for the treatment of DI because they reduce bladder contractions and associated symptoms in most patients. Propanthelene bromide is the second-line drug if patients can tolerate the full dosage. Imipramine should be reserved for carefully selected patients. Flavoxate is not recommended for the treatment of DI. Adrenergic agonists such as norephedrine or ephedrine are the first-line pharmacological therapy for women with GSI who have no contraindications for their use particularly hypertension. Estrogen therapy may be considered as an adjunctive agent for postmenopausal women. Imipramine is recommended as an alternative therapy when either agent has proven unsatisfactory. Duloxetine is a new promising drug for treatment of female GSI pending further clinical experience. There is an urgent medical need for a new smooth muscle agent for treating UI in women because current drug therapy of UI is either inadequate or ineffective. The clinical requirement for treatment of the contractility disorders of the bladder and urethra is drugs that affect the excitability of bladder and urethral smooth muscles with no significant effects on neuronal activity or the contractility of the smooth muscle itself so as to maintain normal micturition. Further clinical experience with drugs that selectively modulate the electrophysiological properties and the intracellular pathways of the smooth muscles of the lower urinary tract in women as therapeutic agents for UI is, therefore, awaited with interest.

References

Erratum

Daudi O. Simba, Mughwira Mwangu

"Application of ICT in strengthening health information systems in developing countries in the wake of globalization"

African Health Sciences 2004; 4(3) 194-198

We regret the omission of Mughwira Mwangu name from the authors of the above article

Editor